RGLS News and Press, Regulus Therapeutics Inc. From 04/30/24

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series PR Newswire SAN DIEGO , April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

2024-04-10 12:51:42 ET Summary Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction of cysts. Additional results from cohort 3 of...

2024-04-09 17:06:43 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics Read the full article on Seeking Alpha For...

2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...

2024-03-21 16:46:41 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics Read the full article on Seeking Alpha For...

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Domin...

2024-03-13 06:18:00 ET 3 Ways How Communities Impact Penny Stocks in 2024 The impact of communities on penny stocks has become increasingly significant, especially with the rise of social media and investment platforms. In 2024, this trend continues to shape the landscape of trading p...

2024-03-12 12:21:11 ET More on Mid-day movers & stocks. FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips ...

Regulus Therapeutics Inc. (NASDAQ: RGLS) is one today's most active stocks by volume. So far today, approximately 76.96M shares of Regulus Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 54,867 shares. Regulus Therapeutics Inc., a clinical stage biopharmaceuti...

2024-03-12 08:38:03 ET Regulus Therapeutics ( NASDAQ: RGLS ) shares rose 68.84% at $2.33  after it entered into a securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. Under the securities p...